{"id":"NCT01479868","sponsor":"Janssen R&D Ireland","briefTitle":"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1","officialTitle":"A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2011-11-28","resultsPosted":"2014-10-29","lastUpdate":"2014-10-29"},"enrollment":109,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Genotype-1"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Pegylated interferon alpha-2a","otherNames":[]},{"type":"DRUG","name":"Ribavirin","otherNames":[]}],"arms":[{"label":"TMC435 + pegylated interferon alpha-2a + ribavirin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects, co-infected with human immunodeficiency virus-type 1, and to evaluate the number of patients with sustained virologic response (SVR) at 12 weeks after the planned end of treatment.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)","timeFrame":"12 weeks after end of treatment (Week 24 or 48)","effectByArm":[{"arm":"TMC435 150mg 12Wks PR24/48","deltaMin":73.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":32,"countries":["United States","Canada","France","Germany","Portugal","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["26753774","26743093","25192745"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":106},"commonTop":["Fatigue","Headache","Neutropenia","Nausea","Anaemia"]}}